Showing 9911-9920 of 20328 results for "".
- Addressing OUD Stigma: Impactful Strategies in Pharmacy Educationhttps://reachmd.com/news/addressing-oud-stigma-impactful-strategies-in-pharmacy-education/2485073/The Let's Talk Stigma program underwent a mixed-methods evaluation combining pre–post surveys, attendance logs, and qualitative interviews to assess reach,
- Impact of Basal Luteinizing Hormone Levels on IVF Outcomes in PCOS: Clinical Insightshttps://reachmd.com/news/impact-of-basal-luteinizing-hormone-levels-on-ivf-outcomes-in-pcos-clinical-insights/2485076/Elevated basal LH in women with PCOS preserves metaphase II oocyte yield and embryo quality during IVF/ICSI but amplifies ovarian responsiveness and OHSS risk — making basal LH a useful pre-cycle risk signal to guide stimulation protocol choice and mitigation planning.
- Genetic and Social Influences on the Gut Microbiome: Implications for IBDhttps://reachmd.com/news/genetic-and-social-influences-on-the-gut-microbiome-implications-for-ibd/2485072/A Center for Genomic Regulation study finds in a large outbred‑rat cohort that genetic and social influences on the gut microbiome converge in
- Advancing Neurosurgical Practices: FDA Approvals and Contemporary Trial Insightshttps://reachmd.com/news/advancing-neurosurgical-practices-fda-approvals-and-contemporary-trial-insights/2485079/The FDA has expanded the indication for TRUFILL n-BCA to permit middl
- Orelabrutinib: A Leap Forward in SLE Therapy from Phase IIb to Phase IIIhttps://reachmd.com/news/orelabrutinib-a-leap-forward-in-sle-therapy-from-phase-iib-to-phase-iii/2485087/Orelabrutinib met its primary endpoint in a Phase IIb study
- Facilitators and Barriers in Mediterranean Diet Adherence: Insights from a Lifestyle Trialhttps://reachmd.com/news/facilitators-and-barriers-in-mediterranean-diet-adherence-insights-from-a-lifestyle-trial/2485083/In a qualitative study of 24 older Spanish adults enrolled in a lifestyle trial of the Mediterranean diet, semi-structured interviews and thematic analysi
- Acne Incidence Higher with Higher-Dose LNG-IUS, Meta-Analysis Findshttps://reachmd.com/news/acne-incidence-higher-with-higher-dose-lng-ius-meta-analysis-finds/2485045/A new systematic review and meta-analysis shows the incidence of acne among users of the levonorgestrel-releasing intrauterine system (LNG-IUS), identifying both dosage and age as influential factors. The review included nine ra
- Understanding the Impact of Sex Hormones on Circadian Clocks: Clinical Insightshttps://reachmd.com/news/understanding-the-impact-of-sex-hormones-on-circadian-clocks-clinical-insights/2485052/A recent study indicates that sex hormones can reset cellular circadian clocks via a protein mediator — a finding with potential implications
- The Kenyan Psoriasis Registry: Early Insights into Clinical Profiles and Treatment Patternshttps://reachmd.com/news/the-kenyan-psoriasis-registry-early-insights-into-clinical-profiles-and-treatment-patterns/2485055/The Kenyan Psoriasis Registry delivers the first systematic, longitudinal dataset on psoriasis in Kenya, offering immediate real‑world evidence to inform screening priorities
- TALON Study Informs on Brolucizumab vs. Aflibercept in nAMD Treatmenthttps://reachmd.com/news/talon-study-informs-on-brolucizumab-vs-aflibercept-in-namd-treatment/2485056/The TALON study found that brolucizumab supported longer treat‑and‑extend intervals at Week 64 without loss of visual‑acuity efficacy versus aflibercept. The 64‑week trial used an iden